Introduction
============

Atopic dermatitis is a chronic cutaneous inflammatory disease in childhood that often persists into adulthood \[[@B2]\]. It is characterized by pruritic skin lesions and frequently associated with allergic asthma disease, and atopic diathesis, or both. The syndrome of atopy may include allergic rhino conjunctivitis, allergic asthma, and atopic dermatitis; most cases of moderate to severe atopic dermatitis do not respond adequate to any single therapeutic modality and many management strategies based on systemic or local corticosteroids are limited by their systemic toxicities. Currently, we do not have effective pharmacological monotherapies with acceptable safety profiles to control the symptoms of this disease in the long run.

Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody for use in IgE-mediated allergic asthma. The efficacy of omalizumab has been extensively evaluated in several clinical studies in patients with predominantly severe persistent allergic asthma \[[@B3],[@B5],[@B6],[@B11]\]. Omalizumab has proven effective over a wide range of outcome measures including asthma exacerbation rates, total emergency visit rates, and quality of life (QoL). Both diseases \-- asthma and atopic dermatitis \-- are associated with elevated serum IgE levels, that are strongly increased in patients with atopic dermatitis. Indeed, omalizumab has been experimentally used in various atopic skin diseases including atopic dermatitis with high IgE levels. Efficacy of omalizumab in atopic skin diseases is heterogeneous and ranges from very good efficacy to no effect at all in case reports and small studies \[[@B7]-[@B9],[@B13],[@B14]\]. However, no data exist on the evaluation of omalizumab treatment in patients with both atopic dermatitis and asthma.

The aim of the present study was to evaluate the efficacy and safety of omalizumab in patients with concomitant asthma and atopic dermatitis versus those with asthma alone. In particular, we were interested in changges of quality of life and asthma control.

Methods
=======

In a prospective monocenter investigation we assessed a series of 22 atopic patients with omalizumab therapy for 12 months starting between July 2006 and October 2008. Inclusion criteria for all patients were identical to that of the INNOVATE study \[[@B6],[@B12]\] - except serum IgE levels (≥ 30 to ≤ 700 IU/ml). Inclusion criteria were very strict in order to enrol the most severe patients with persistent allergic asthma (12-75 years): Positive skin prick test to ≥ 1 perennial aeroallergen, to which they were likely to be exposed during the study, severe persistent asthma requiring regular treatment with \> 1000 μg/day beclomethason dipropionate or equivalent and long-acting β2-agonist (Global Initiative for Asthma (GINA) step 4 treatment), forced expiratory volume in 1 s (FEV1) ≥ 40 to \< 80% of predicted normal value and continuing asthma symptoms, FEV1 reversibility ≥ 12% from baseline within 30 min of inhaled (up to 400 μg) or nebulized (up to 5 mg) salbutamol, despite high-dose ICS and LABA use at least two asthma exacerbations requiring systemic corticosteroids, or one severe exacerbation \[peak expiratory flow (PEF)/FEV1 \< 60% of personal best, requiring systemic corticosteroids\] resulting in hospitalization or emergency room treatment, in the past 12 months. Thirteen patients with allergic asthma served as controls, and 9 patients with concomitant allergic asthma and atopic dermatitis were included. Patients with allergic asthma alone had a mean FEV1 of 71% of predicted, patients with concomitant atopic dermatitis of 76% (Table [1](#T1){ref-type="table"}).

###### 

Patient characteristics, asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI), and asthma-related treatment at baseline and after 6 and 12 months omalizumab therapy

                      Asthma        Asthma + atopic dermatitis   P value
  ------------------- ------------- ---------------------------- ----------
  Age (years)         47.5 ± 14.8   38.1 ± 11.3                  0.127
  Sex /female)        10/13 77%     6/9 67%                      0.394
  IgE                 212 ± 224     3528 ± 2723                  \< 0.001
  FEV1                71.5 ± 10,7   76.2 ± 7,4                   0.350
  Weight in kg        82.3 ± 22.0   76.3 ± 16.1                  0.472
  Omalizumab dosage                                              
  (mg/2 weeks)        213 ± 86      233 ± 109                    0.654
  OCS baseline        12/13         7/9                          0.394
  OCS 6 month         4/13          0/9                          0.003
  OCS 12 month        4/13          0/9                          0.003
  AQlQ baseline       102 ± 40      143 ± 44                     0.041
  AQlQ 6 month        148 ± 48      175 ± 40                     0.041
  AQlQ 12 month       152 ± 45      170 ± 42                     0.04
  DlQI baseline                     19 ± 10                      
  DlQI 6 month                      7 ± 8                        
  DlQI 12 moth                      6 ± 6                        

OCS, oral corticosteroids, ICS, inhaled corticosteroids.

Whereas total serum IgE levels were \> 30 to \< 700 IU/ml (mean 212 ± 224 IU/ml) in patients with asthma alone, all patients with concomitant atopic dermatitis displayed total serum IgE values above 700 IU/ml (mean 3,528 ± 2,723 IU/ml). The dose of omalizumab (Xolair, Novartis, Nürnberg, Germany) was dependent on body weight and serum IgE levels and was administered every 2 or 4 weeks, as described \[[@B3],[@B6]\]. Patients with concomitant atopic dermatitis were treated regardless of IgE values with 150 mg s.c. in 14 day intervals based on the observation of previous work \[[@B1],[@B10]\]. Omalizumab dosage was increased up to a improvement of dermatological status; dosage did not exceed the maximal two week-dosage of 450 mg s.c. Asthma-related quality of life (AQLQ), atopic dermatitis related quality of life (DLQI) \[[@B4]\], and treatment with oral steroids were compared between both groups at baseline and 1, 2, 3, 6 and 12 months after initiating omalizumab treatment. Adverse events were recorded at each treatment visit. 5 additional patients with asthma alone were excluded from study analysis due to anaphylactic reaction after first omalizumab injection (n = 1) or discontinuation of therapy due to unsatisfactory therapeutic effect on asthma despite correct dosage within the first six months (n = 4).

Statistical Analysis
--------------------

Probability was calculated with the students t-test; P values of \< 0.05 were considered to be statistically significant. All studies have been carried out according to the Helsinki declaration of good clinical practice.

Results
=======

Patient characteristics, such as age, gender, and medication did not differ between patients with asthma (n = 13) and patients with concomitant asthma and atopic dermatitis (n = 9) and are presented in Table [1](#T1){ref-type="table"}. All patients were receiving inhaled corticosteroids (\> 1000 μg/day beclomethason dipropionate or equivalent) and long-acting β2-agonists (fixed combination of fluticason/salmeterol or budesonid/formeterol), 12/13 of patients with asthma and 7/9 of patients with asthma/atopic dermatitis received additional maintenance oral corticosteroid at baseline. Consistently, patients with asthma and atopic dermatitis showed significantly higher serum IgE values than patients with asthma alone (3,528 ± 2,723 IU/ml vs. 212 ± 224 IU/ml, P \< 0.001). Of note, there was no significant difference between both groups regarding the omalizumab dosage.

AQLQ was improved for the total collective (P = 0.01) and in the asthma alone group after 6 months (P = 0.01), while no change was seen in AQLQ in the atopic dermatitis/asthma group (P = 0.12) (Figure [1](#F1){ref-type="fig"}). There were no significant changes at earlier time points. DLQI was significantly in favor of omalizumab after 2 months in the asthma/atopic dermatitis group (P = 0.01); this effect was seen until 12 months (Figure [2](#F2){ref-type="fig"}). Overall improvements in DLQI indices as well as in minimizing topic corticosteroids in skin therapy were found in all patients with asthma/atopic dermatitis. During treatment, both patient groups lowered their use of oral corticosteroids: All (9/9) patients with asthma/atopic dermatitis discontinued oral corticosteroid use, whereas 9/13 patients with asthma alone stopped this therapy.

![**Time course of AQLQ for patients with asthma alone (red) and concomitant atopic dermatitis and asthma (blue)**. AQLQ was improved in the asthma alone group after 6 months omalizumab treatment (P \< 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline), while no significant change was seen in AQLQ in the atopic dermatitis/asthma group.](2047-783X-16-9-407-1){#F1}

![**Time course of DLQI that was significantly in favor of omalizumab treatment in the atopic dermatitis/asthma group (P \< 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline)**.](2047-783X-16-9-407-2){#F2}

Baseline IgE, age, body weight, FEV1 and dosage of omalizumab do not predict response to omalizumab.

Overall, 4 of the 22 patients having received 12 months omalizumab (18%) experienced at least one adverse effect: headache (n = 1), local reaction at point of injection (n = 4) and nausea (n = 1).

Discussion
==========

The present study is the first designed to evaluate the efficacy of omalizumab on quality of life (QoL) in patients with concomitant asthma and atopic dermatitis. Omalizumab is effective in improving atopic dermatitis-related QoL scores and modulates oral corticosteroid treatment. All patients had severe persistent asthma as defined by Global Initiative for Asthma (GINA) guidelines \[[@B12]\]. Omalizumab was used as an add-on treatment to standard management. Indeed, improvement in asthma QoL in the groups was similar and comparable to other reports with omalizumab \[[@B3],[@B6]\]. In addition, in the comorbid population suffering from atopic dermatitis and asthma, treatment with omalizumab resulted in significant improvements of atopic dermatitis-related QoL and in reduction of use of oral corticosteroids. Choice of the long-term observational interval (\> 12 months) was based on the possibility and variability of placebo-induced clinical improvement in atopic dermatitis. This phenomenon was described in the first three months of observation period in up to 40% of the cases after initiation of a new treatment option \[[@B1]\]. Of interest, changes in atopic dermatitis-related QoL were seen 2 months after initiating omalizumab treatment, whereas improved asthma QoL reached significance only after 6 months.

Of note, the present improvement of QoL scores in patients with concomitant atopic dermatitis and asthma was observed with low-dose anti IgE treatment (233 ± 109 mg/2 weeks) and, therefore, was in a much lower dosage than required for the complete removal of IgE from the circulation, as recently also described by Lim and Belloni \[[@B1],[@B10]\]. They had observed free IgE remained basically stable over the omalizumab treatment period and suggested other, molecular effects such as a switch to reduced IgE mRNA production responsible for skin improvement \[[@B1],[@B10]\]. One may speculate, that those patients with lower IgE levels would show a better QoL improvement, however, this is not shown by the present data. Indeed, mean IgE level 3,528 ± 2,723 IU/ml in the present study is even higher than in previous studies, for example 1,521 IU/ml in the work of Sheinkopf and colleagues \[[@B13]\].

There are several limitations of this single-center project with a small study collective that was designed as a pilot study, not as a randomized trial. The concept that underlies this study was the screening of the impact on quality of life brought on by omalizumab description in patients with atopic disease, as seen in \"daily practice\".

In conclusion, this study extends previously published reports on omalizumab in atopic dermatitis \[[@B1],[@B10],[@B13]\] by integrating patients with concomitant asthma and atopic dermatitis and found that omalizumab is significantly efficacious in improving disease-related QoL when added to standard asthma and atopic dermatitis therapies. Further placebo-controlled studies in this patient collective are warranted.
